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The apolipoprotein E (APOE) gene is the only genetic risk factor that has so far been linked to risk for late-onset Alzheimer's disease (LOAD). However, 50 percent of Alzheimer's disease cases do not carry an APOE4 allele, suggesting that other risk factors must exist. We performed a two-stage genome-wide screen in sibling pairs with LOAD to detect other susceptibility loci. Here we report evidence for an Alzheimer's disease locus on chromosome 10. Our stage one multipoint lod score (logarithm of the odds ratio for linkage/no linkage) of 2.48 (266 sibling pairs) increased to 3.83 in stage 2 (429 sibling pairs) close to D10S1225 (79 centimorgans). This locus modifies risk for Alzheimer's disease independent of APOE genotype.
Mutations in three genes encoding ␤-amyloid precursor protein (APP), presenilin 1, and presenilin 2 cause the rare, early-onset autosomal dominant form of Alzheimer's disease (AD) (1) . These mutations all affect APP metabolism such that more A␤42 peptide is produced (2) . In contrast, most AD cases have ages of onset above 65 years and exhibit no clear pattern of inheritance (late-onset Alzheimer's disease or LOAD). The E4 allele of the apolipoprotein E (APOE) gene is the only known genetic risk factor for LOAD (3, 4) . However, 50% of LOAD cases carry no APOE4 alleles, indicating that there must be additional risk factors (4) . To look for other susceptibility loci, we performed a two-stage genome-wide screen in affected Caucasian sibling pairs (ASPs). Each sibling used for analysis had an age of onset Ն65 years and a diagnosis of definite or probable AD. If there were more than two affected siblings within a family, all siblings were sampled and genotyped. In stage 1, 292 ASPs were genotyped with markers spaced about 20 centimorgans (cM) apart throughout the genome (5, 6) . Nonparametric methods, which do not require the mode of inheritance to be specified, were used to analyze these data in the whole sample and in two subsamples stratified by APOE4 genotype. We observed 16 chromosomal regions with a multipoint logarithm of the odds ratio for linkage/no linkage (lod score) (MLS) Ն 1 (6) . Four of the sixteen peaks, including one on chromosome 10, met the criteria for "suggestive" linkage (7).
For stage 2, markers within the stage 1 peaks were genotyped in an additional 168 ASPs (83 newly ascertained in the United Kingdom, 80 obtained from the Indiana Alzheimer Disease Center National Cell Repository, and 5 from the National Institute of Mental Health Genetics Initiative) (8). On chromosome 10, 15 additional markers were genotyped in all 429 ASPs, reducing the average interval to 5 cM. Two-point analyses were carried out between each marker locus and the disease with the program SPLINK (9), which was also used to estimate marker allele frequencies for the multipoint analyses. The highest two-point lod scores, 3.10 in stage 1 and 4.85 in stage 2, were obtained in the whole sample with marker D10S1211 (at 82.2 cM on the multipoint map). On average, 50% of the siblings share alleles at any given locus. However, 64% of ASPs share alleles for D10S1211. Elevated allele sharing and positive lod scores were observed in the whole sample and in APOE4ϩve ( pairs where both siblings had at least one APOE4 allele) and APOE4-ve ( pairs where neither sibling had an APOE4 allele) sibling pairs in an extended region around D10S1211 (10) .
Multipoint linkage analyses were carried out with the program MAPMAKER/SIBS (11) on the whole sample, on pairs where both siblings had at least one APOE4 allele, and on pairs where neither sibling had an APOE4 allele (Fig. 1) . These analyses use information from adjacent markers to determine the most likely location of the disease susceptibility allele. The stage 1 maximum MLS of 2.48 at 77.6 cM is slightly different from that previously reported (6 ) and reflects changes in diagnoses. This lod score increased to 3.83 at 79 cM in stage 2 (between D10S1227 and D10S1225). An MLS of 3.83 would be expected to occur by chance 0.01 times per genome scan, considering the whole-sample analysis alone (or ϳ0.05 per genome allowing for all three analyses) (12) . The stage 2 analysis of APOE4ϩve ASPs gave a maximum MLS of 2.78 at D10S1225, whereas the APOE4-ve pairs gave a maximum MLS of 0.66 at 85.4 cM. However, allele sharing was similarly elevated (to 59%) in all three subgroups, indicating that stratification of the sample by APOE4 did not change the proportion of allelic sharing at the peak.
In conclusion, we have confirmed our preliminary observation of a region of suggestive linkage on chromosome 10 (6 ), providing strong evidence for a susceptibility locus for LOAD. This locus was robustly detected in both stages of our genome screen and shows a maximum MLS greater than that observed in the same data set on chromosome 19 around the APOE locus. This suggests that the chromosome 10 locus is a major risk factor for LOAD. Indeed, we estimate the chromosome 10 locus-specific 's (relative risk to siblings) to be about equivalent to that for APOE. In the accompanying report by Ertekin-Taner et al. (13) , there is evidence that a quantitative trait locus for high A␤42 levels maps to the same chromosomal region. This suggests that the AD susceptibility allele identified in our study increases risk for disease by modifying A␤42 metabolism. (11) on the whole sample (429 pairs), on pairs where both siblings had at least one APOE4 allele (APOE4ϩve; 262 pairs), and on pairs where neither sibling had an APOE4 allele (APOE4-ve; 83 pairs). The region of linkage for high plasma A␤42 from the Ertekin-Taner et al. (13) report is also shown. Marker distances were taken from the Marshfield database (15) .
